Related Experiment Video
Updated: Feb 18, 2026

In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis
Published on: February 17, 2012
Soft drug-resistant ovarian cancer cells migrate via two distinct mechanisms utilizing myosin II-based contractility
Aastha Kapoor1, Amlan Barai1, Bhushan Thakur2
1Department of Biosciences and Bioengineering, IIT Bombay, India.
Abstract:
The failure of chemotherapeutic drugs in treatment of various cancers is attributed to the acquisition of drug resistance. However, the migration mechanisms of drug-resistant cancer cells remain incompletely understood. Here we address this question from a biophysical perspective by mapping the phenotypic alterations in ovarian cancer cells (OCCs) resistant to cisplatin and paclitaxel. We show that cisplatin-resistant (CisR), paclitaxel-resistant (PacR) and dual drug-resistant (i.e., resistant to both drugs) OCCs are more contractile and softer than drug-sensitive cells. Protease inhibition suppresses invasion of CisR cells but not of PacR cells, indicative of a protease-dependent mode of migration in CisR cells and a protease-independent mode of migration in PacR. Despite these differences, actomyosin contractility, mediated by the RhoA-ROCK2-Myosin II signaling pathway, regulates both modes of migration. Confined migration experiments establish the role of myosin IIA and IIB in mediating nuclear translocation and regulation of proteolytic activity. Collectively, our results highlight the importance of myosin II as a potential therapeutic target for treatment of drug-resistant ovarian cancer cells.
Insights
Drug-resistant ovarian cancer cells exhibit altered biophysical properties, migrating via distinct protease-dependent or -independent pathways. Myosin II is identified as a key regulator and potential therapeutic target for these resistant cells.
Area of Science:
- Biophysics
- Cancer Biology
- Cell Migration
Background:
- Chemotherapeutic drug resistance is a major challenge in cancer treatment.
- The migration mechanisms of drug-resistant cancer cells are not fully understood.
Purpose of the Study:
- To investigate the biophysical properties and migration mechanisms of drug-resistant ovarian cancer cells (OCCs).
- To identify potential therapeutic targets for overcoming drug resistance in ovarian cancer.
Main Methods:
- Phenotypic characterization of cisplatin-resistant (CisR), paclitaxel-resistant (PacR), and dual drug-resistant OCCs.
- Assessment of cell contractility, softness, and invasion.
- Analysis of migration modes using protease inhibition.
- Investigation of the RhoA-ROCK2-Myosin II signaling pathway.
- Confined migration experiments to study nuclear translocation and proteolytic activity.
Main Results:
- Drug-resistant OCCs are more contractile and softer than drug-sensitive cells.
- CisR cells exhibit protease-dependent migration, while PacR cells show protease-independent migration.
- Actomyosin contractility via the RhoA-ROCK2-Myosin II pathway regulates both migration modes.
- Myosin IIA and IIB are crucial for nuclear translocation and proteolytic activity during migration.
Conclusions:
- Ovarian cancer cell migration is modulated by drug resistance and involves distinct biophysical mechanisms.
- Myosin II plays a critical role in the migration of drug-resistant ovarian cancer cells.
- Myosin II represents a promising therapeutic target for treating drug-resistant ovarian cancer.
Related Concept Videos
Role of Myosin in Cell Migration
Myosin II is a hexamer comprising two heavy chains with globular heads and coiled-coil tails, two regulatory light chains, and two essential light chains. The ATPase sites on the myosin heads hydrolyze ATP, and the released phosphate generates the force for contraction....
Cancer Cell Migration through Invadopodia
Cytoskeletal Coordination in Cell Migration
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Cell Migration
Cell Migration

